Takeda’s HyQvia is indicated to treat primary immunodeficiency in children aged between two and 16 years. Credit: Ben Wicks on Unsplash.

The US Food and Drug Administration (FDA) has approved Takeda’s supplemental Biologics Licence Application (sBLA) to expand the use of its HyQvia subcutaneous immune globulin (ScIG) for the treatment of primary immunodeficiency (PI) in children aged between two and 16 years.

HyQvia is a liquid medicine containing recombinant human hyaluronidase and immunoglobulins (Ig). It was previously approved in the US to treat PI in adults.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The drug is claimed to be the only ScIG infusion that can be given once a month.

Takeda US Plasma-Derived Therapies Business Unit head Brandon Monk said: “This expanded HyQvia indication exemplifies our ongoing commitment to providing plasma-derived therapies with proven efficacy.

“HyQvia is now available to a broader community impacted by PI, including children and their families with distinct needs, who may prefer flexible treatment options in the management of these disorders.”

The expanded regulatory approval was based on the data obtained from an open-label, pivotal, non-controlled, prospective Phase III clinical trial conducted in 44 PI patients aged between two years and 16 years.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

HyQvia was found to be effective as a treatment for acute serious bacterial infections. This was a primary endpoint of the trial.

The trial continued for 12 months, and the medicine’s efficacy was further shown by the overall rate of infections per participant.

Takeda noted that the findings from the interim data analysis indicated similar safety profiles to those of adults. There were no clinically meaningful differences in trough immunoglobulin G (IgG) levels across the age groups.

HyQvia is also approved in the European Union (EU) as a replacement therapy in patents of all age groups with PI and secondary immunodeficiency.